Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT05360615

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Conditions: Empagliflozin in Post AKI Stage 2-3

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE1

Enrollment: 147

Sponsor: Chulalongkorn University

Location: Central Chest Institute of Thailand Nonthaburi Mueang Nonthaburi District

Summary

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Eligibility Criteria

Inclusion Criteria: * post AKI stage 2-3 * CrCl \> 20 Exclusion Criteria: * pregnancy * post kidney transplant * previous use of SGLT2 Inhibitors * history of ketoacidosis

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05360615). StuddyBuddy aggregates publicly available trial information.